About
Dr. Ray joined The Column Group in 2017. Previously, Dr. Ray was an Associate of Business Development at Foghorn Therapeutics, which she helped launch with Flagship Pioneering. Dr. Ray helped develop and execute the scientific, business and operating plans for Foghorn Therapeutics. Dr. Ray helped establish the first onsite next-generation sequencers for Ebola viral surveillance with Dr. Pardis Sabeti’s lab at Harvard University and the Broad Institute. Previously, Dr. Ray completed her PhD at Harvard University with Dr. Robert Kingston, studying the effects of long non-coding RNAs on epigenetic regulation. Dr. Ray holds undergraduate degrees in Biology and Mathematics from the Massachusetts Institute of Technology, where she also performed embryonic stem cell research in the lab of Dr. Rudolf Jaenisch.
Position in the VCSift Database
- • 8 investors at The Column Group are tracked.
- • 2,531 investors hold the Partner role in VCSift. Millie Ray is one of them.
- • 2,799 investors are based in United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- US
Contact Information
Find more investors like Millie
Search Investors